GlassScriptPhysician profile
Elie M Osta
NPI 1861468902
$1,789.04
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $57.98 · 2021: $516 · 2022: $304 · 2023: $415 · 2024: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $247.17 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Sanofi-Aventis U.S. LLC | $211.76 | 2019-2022 | |
| Novo Nordisk INC | $183.11 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Nestle Healthcare Nutrition INC. | $137.79 | 2020-2022 | |
| Abbott Laboratories | $113.48 | 2021-2023 | Freestyle Libre 2 |
| Corcept Therapeutics | $111.04 | 2023-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $106.52 | 2019-2024 | Farxiga |
| Amgen INC. | $89.30 | 2022-2024 | Repatha, Otezla, Krystexxa |
| Insulet Corporation | $71.25 | 2021-2023 | Omnipod |
| Astellas Pharma US INC | $64.05 | 2019-2023 | Veozah |
| Abbvie INC. | $55.34 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $52.57 | 2021 | |
| Pfizer INC. | $47.03 | 2019-2023 | |
| Dexcom, INC. | $40.38 | 2022-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $38.05 | 2024 | Wavewriter Alpha Prime 16 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.96 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $29.53 | 2023 | Nuedexta |
| Novartis Pharmaceuticals Corporation | $22.60 | 2021 | |
| Glaxosmithkline, LLC. | $18.56 | 2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $16.28 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $15.52 | 2023 | Prehevbrio |
| Exact Sciences Corporation | $15.32 | 2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $14.32 | 2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.38 | 2020 | |
| Allergan, INC. | $12.10 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.72 | 2021 | |
| Corium, LLC | $8.37 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elie Osta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.